FGI-104 explained

FGI-104 is the name of an experimental broad-spectrum antiviral drug, with activity against a range of viruses including hepatitis B, hepatitis C, HIV, Ebola virus, and Venezuelan equine encephalitis virus. ^[1]

Mechanism

The drug acts by inhibiting the protein TSG101, which transports newly manufactured virions to the exterior of an infected cell, thus breaking the replication cycle of the virus. In pre-clinical studies, FGI-104 has been shown to protect mice from Ebola virus disease.^{[2] [3]}

See also

• FGI-103
• FGI-106
• LJ-001

Notes and References

1. Kinch MS, Yunus AS, Lear C, Mao H, Chen H, Fesseha Z, Luo G, Nelson EA, Li L, Huang Z, Murray M, Ellis WY, Hensley L, Christopher-Hennings J, Olinger GG, Goldblatt M . 6 . FGI-104: a broad-spectrum small molecule inhibitor of viral infection . American Journal of Translational Research . 1 . 1 . 87–98 . January 2009 . 2776286 . 10.1016/j.antiviral.2009.02.082 . 19966942 .
2. Janeba Z . Development of Small-Molecule Antivirals for Ebola . Medicinal Research Reviews . 35 . 6 . 1175–94 . November 2015 . 26172225 . 7168439 . 10.1002/med.21355 .
3. Book: Saxena A, Ferri M . Communicable Diseases of the Developing World . Clinical Management of Ebola Virus Disease: Current and Future Approaches . 2015 . Saxena A . Topics in Medicinal Chemistry . 29 . 1–36 . Springer . Cham . 10.1007/7355_2015_5003 . 978-3-319-78252-2 .